Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston Scientific Corporation

http://www.bostonscientific.com

Latest From Boston Scientific Corporation

News We’re Watching: Regulatory Clearances For Illumina, GE, Boston Scientific; FDA Patient Group To Meet In October; Johns Hopkins Joins AI Accelerator

This week, Illumina announced its new CDx has FDA approval; GE and Boston Scientific nabbed CE marks; and the FDA’s Patient Engagement Advisory Committee announced that its October meeting will focus on informed consent in clinical trials.

Approvals Commercial

Biocon Expects US Adalimumab Market To Consolidate, Liraglutide Plans On Course

Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.

Sales & Earnings Strategy

Finance Watch: Lykos Implements 75% Workforce Reduction After FDA Rejection

Restructuring Edition: Lykos recruited a J&J veteran to help its slimmed-down staff resubmit its MDMA-based PTSD therapy. Also, Lexicon cut its field force by 50%, or 75 jobs; Viracta cut its solid tumor program and 23% of its workforce; and Boundless Bio streamlined with moderate job cuts.

Financing Restructuring

Biocon Expects US b(Humira) Market To Consolidate, Liraglutide Plans On Course

Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.

Sales & Earnings Biosimilars
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Monitoring Equipment & Devices
    • Radiofrequency Devices
    • Rehabilitation Equipment and Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
    • Diagnostic Imaging Equipment & Supplies
      • Digital Imaging
  • Other Names / Subsidiaries
    • Apama Medical
    • Asthmatx
    • Atritech, Inc.
    • Augmenix, Inc.
    • Biocompatibles International plc
    • BridgePoint Medical, Inc.
    • BTG plc
    • BTG Specialty Pharmaceuticals
    • Cameron Health, Inc.
    • Cardiovascular Imaging Systems, Inc.
    • CellMed
    • Cosman Medical Inc.
    • CryoCor
    • Cryterion Medical, Inc.
    • Devoro Medical, Inc.
    • Ekos Corporation
    • EMcision, Ltd.
    • EndoTex Interventional Systems, Inc.
    • EndoChoice Holdings, Inc.
    • Enteric Medical Technologies, Inc.
    • Galil Medical, Inc.
    • Guidant Corporation
    • Intelect Medical, Inc.
    • IoGyn, Inc.
    • Labcoat Limited
    • Meadox Medicals, Inc.
    • Novate Medical Ltd.
    • nVision Medical Corporation
    • NxThera, Inc.
    • Pathworks Anatomic Pathology Laboratory
    • PneumRx Inc.
    • Precision Vascular Systems, Inc.
    • Protherics PLC
    • RadioTherapeutics Corporation
    • Revascular Therapeutics, Inc.
    • Roxwood Medical
    • Rubicon Medical Corporation
    • SCIMED, Inc.
    • Securus Medical Group, Inc.
    • Symetis SA
    • VENITI
    • Vessix Vascular, Inc.
    • Xlumena Inc.
UsernamePublicRestriction

Register